Some studies also discusses how blocking CD38 can potentially reduce kidney injury and explores the therapeutic potential of CD38 monoclonal antibodies for kidney diseases like allergic purpura nephritis and granulomatous polyangiitis (51–53). Here, CD38 is linked to kidney disorder.